基本信息
浏览量:1
职业迁徙
个人简介
Description of Research Expertise
Allogeneic blood or marrow transplantation is the only potentially curative option for patients with relapsed, refractory, or high-risk hematologic malignancies. Unfortunately, only a third of patients have an available HLA-matched related donor. Partially HLA-mismatched related (HLA-haploidentical) transplantation allows identification of a donor for the vast majority of patients. In the past, HLA-haploidentical transplantation was associated with excessive nonrelapse mortality and poor overall survival. My research has contributed to the understanding of a novel technique that utilizes post-transplant cyclophosphamide as graft-versus-host disease prophylaxis after HLA-haploidentical transplantation. Using risk stratification with the disease risk index developed by Armand et al., I demonstrated that outcomes after nonmyeloablative HLA-haploidentical transplantation are comparable to that after reduced intensity HLA-matched transplantation. Similar to my work in older patients described above, I have also shown that nonmyeloablative HLA-haploidentical transplantation is safe and effective for pediatric and young adult patients. In addition, I have contributed to research examining early biomarkers, such as ST2, as predictors of nonrelapse mortality after HLA-haploidentical transplantation. Finally, to improve outcomes further, I have conducted research to examine the association of donor characteristics with transplantation outcomes. I showed that parent donors were associated with more graft failure when compared with sibling or offspring donors, but that survival was no different. Importantly, in that analysis, survival was affected by recipient age with recipients over 55 having inferior survival to younger patients. This work supports my proposed research agenda to evaluate the utility of the frailty phenotype tools to predict an older patient’s risk of nonrelapse mortality after induction chemotherapy and allogeneic transplantation as discussed in this proposal. Finally, my research has contributed to the widespread adoption of HLA-haploidentical transplantation with post-transplant cyclophosphamide, I have advanced the understanding of how we can improve its outcomes further, and I hope to continue to advance the field through studying frailty phenotype assessments in older patients with leukemia and myeloid malignancies undergoing induction then consolidative allogeneic transplantation.
Allogeneic blood or marrow transplantation is the only potentially curative option for patients with relapsed, refractory, or high-risk hematologic malignancies. Unfortunately, only a third of patients have an available HLA-matched related donor. Partially HLA-mismatched related (HLA-haploidentical) transplantation allows identification of a donor for the vast majority of patients. In the past, HLA-haploidentical transplantation was associated with excessive nonrelapse mortality and poor overall survival. My research has contributed to the understanding of a novel technique that utilizes post-transplant cyclophosphamide as graft-versus-host disease prophylaxis after HLA-haploidentical transplantation. Using risk stratification with the disease risk index developed by Armand et al., I demonstrated that outcomes after nonmyeloablative HLA-haploidentical transplantation are comparable to that after reduced intensity HLA-matched transplantation. Similar to my work in older patients described above, I have also shown that nonmyeloablative HLA-haploidentical transplantation is safe and effective for pediatric and young adult patients. In addition, I have contributed to research examining early biomarkers, such as ST2, as predictors of nonrelapse mortality after HLA-haploidentical transplantation. Finally, to improve outcomes further, I have conducted research to examine the association of donor characteristics with transplantation outcomes. I showed that parent donors were associated with more graft failure when compared with sibling or offspring donors, but that survival was no different. Importantly, in that analysis, survival was affected by recipient age with recipients over 55 having inferior survival to younger patients. This work supports my proposed research agenda to evaluate the utility of the frailty phenotype tools to predict an older patient’s risk of nonrelapse mortality after induction chemotherapy and allogeneic transplantation as discussed in this proposal. Finally, my research has contributed to the widespread adoption of HLA-haploidentical transplantation with post-transplant cyclophosphamide, I have advanced the understanding of how we can improve its outcomes further, and I hope to continue to advance the field through studying frailty phenotype assessments in older patients with leukemia and myeloid malignancies undergoing induction then consolidative allogeneic transplantation.
研究兴趣
论文共 111 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Shannon R. McCurdy,Mustafa A. Hyder, Ruby Sabina, Ashley DeVries, Kirstin Chalupa, Natasha Berryman, Jessica Bernhardt,Alison Christina Cusmano,Amy Chai, Rebecca Schwartz,Dimana Dimitrova,Kamil Rechache,Christi McKeown,Anita Stokes,Jennifer Sponaugle,Noelle V. Frey,Saar I. Gill,Elizabeth O Hexner,Mary Ellen Martin,Nasheed Hossain
Transplantation and Cellular Therapyno. 2 (2024): S2-S3
FRONTIERS IN IMMUNOLOGY (2024): 1358668-1358668
Yu Kang,Benedicte Lefebvre, Ingrid Marti Pamies,Saar I Gill, Abigail G. Doucette,Srinivas Denduluri,Amanda M. Smith,Shannon McCurdy,Selina Luger,Joseph Carver,Marielle Scherrer-Crosbie
The American Journal of Cardiology (2024): 9-17
Journal of the American College of Cardiologyno. 13 (2024): 2585
Transplantation and Cellular Therapyno. 2 (2024): S407-S408
Piyanuch Kongtim,Pongthep Vittayawacharin, Jun Zou, Samer Srour,Brian Shaffer, Roman M. Shapiro,Ankur Varma,Joseph McGuirk,Bhagirathbhai R. Dholaria,Shannon R. McCurdy, Amy E. DeZern,Nelli Bejanyan,Asad Bashey, Sabine Furst, Luca Castagna, Jacopo Mariotti, Annalisa Ruggeri, Rebeca Bailen, Takanori Teshima,Huang Xiao-Jun
Transplantation and Cellular Therapy (2024)
Journal of Clinical Oncologyno. 16_suppl (2024)
Mustafa A. Hyder,Shannon R. McCurdy, Ruby Sabina, Ashley DeVries, Kirstin Chalupa, Natasha Berryman, Jessica Bernhardt,Alison Christina Cusmano,Amy Chai, Rebecca Schwartz,Dimana Dimitrova,Kamil Rechache,Christi McKeown,Anita Stokes,Jennifer Sponaugle,Noelle V. Frey,Saar I. Gill,Elizabeth O Hexner,Mary Ellen Martin,Nasheed Hossain
Transplantation and Cellular Therapyno. 2 (2024): S284-S285
Anthony D Sung,Thuy Koll,Shannon H Gier,Alessandro Racioppi,Griffin White,Meagan Lew, Marcia Free,Priyal Agarwal,Lauren M Bohannon,Ernaya J Johnson,Bharathi Selvan,Daria V Babushok,Noelle V Frey,Saar I Gill,Elizabeth O Hexner, MaryEllen Martin,Alexander E Perl,Keith W Pratz,Selina M Luger,Nelson J Chao,Alfred L Fisher,Edward A Stadtmauer,David L Porter,Alison W Loren,Vijaya R Bhatt,Phyllis A Gimotty,Shannon R McCurdy
Transplantation and cellular therapyno. 4 (2024): 415.e1-415.e16
American journal of hematologyno. 5 (2024): 922-937
加载更多
作者统计
#Papers: 111
#Citation: 2092
H-Index: 24
G-Index: 45
Sociability: 6
Diversity: 2
Activity: 30
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn